We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

21 hedge funds and large institutions have $85.2M invested in UroGen Pharma in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39.41% more ownership

Funds ownership: 0% → 39.41% (+39%)

Holders
21
Holders Change
+21
Holders Change %
–
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
+$25.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.4M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.1M
4
HCM
Highline Capital Management
New York
+$7.38M
5
HIM
Hillhouse Investment Management
Cayman Islands
+$6.12M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PAI
1
ProQuest Associates IV
Florida
$26.2M +$25.2M +1,451,329 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$13.9M +$13.4M +769,230 New
Wellington Management Group
3
Wellington Management Group
Massachusetts
$13.6M +$13.1M +752,740 New
HCM
4
Highline Capital Management
New York
$7.68M +$7.38M +425,300 New
HIM
5
Hillhouse Investment Management
Cayman Islands
$6.36M +$6.12M +352,300 New
PA
6
Perceptive Advisors
New York
$4.86M +$4.67M +269,014 New
Jennison Associates
7
Jennison Associates
New York
$3.17M +$3.05M +175,410 New
WCM
8
Wildcat Capital Management
New York
$2.44M +$2.34M +135,000 New
MMH
9
Menora Mivtachim Holdings
Israel
$2.33M +$2.24M +129,055 New
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$903K +$868K +50,000 New
SIM
11
Spark Investment Management
New York
$856K +$823K +47,400 New
CBA
12
Coastal Bridge Advisors
Connecticut
$695K +$668K +38,461 New
MIM
13
Monashee Investment Management
Massachusetts
$594K +$571K +32,908 New
Norges Bank
14
Norges Bank
Norway
$540K +$519K +29,900 New
PL
15
Parkwood LLC
Ohio
$500K +$481K +27,694 New
JMPWA
16
JP Morgan Private Wealth Advisors
California
$221K +$213K +12,250 New
AA
17
ALPS Advisors
Colorado
$195K +$188K +10,806 New
Deutsche Bank
18
Deutsche Bank
Germany
$136K +$131K +7,560 New
UBS Group
19
UBS Group
Switzerland
$7K +$6.48K +373 New
CCA
20
Catalyst Capital Advisors
New York
$7K +$6.6K +380 New
TRCT
21
Tower Research Capital (TRC)
New York
$5K +$4.84K +279 New

URGN Hedge Fund Activity: Q2 2017 in Review

21 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2017, worth a combined $85.2M.

Buyers outnumbered sellers: 21 funds opened new URGN positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was ProQuest Associates IV, opening a new position worth an estimated $25.2M.

  • 21 institutional investors held UroGen Pharma (URGN) as of Q2 2017, up from 0 in Q1 2017.
  • Funds reported $85.2M of UroGen Pharma stock for Q2 2017.
  • 21 funds opened new UroGen Pharma positions in Q2 2017 and 0 closed out, a net change of +21 holders.
  • The largest UroGen Pharma buyer in Q2 2017 was ProQuest Associates IV, an estimated $25.2M added.

Based on aggregated 13F filings for Q2 2017.